abrdn plc Decreases Stake in uniQure (NASDAQ:QURE)

abrdn plc reduced its stake in uniQure (NASDAQ:QURE) by 21.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,509,335 shares of the biotechnology company’s stock after selling 419,726 shares during the period. abrdn plc owned about 3.10% of uniQure worth $26,655,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. RTW Investments LP purchased a new position in uniQure in the 3rd quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. increased its stake in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc purchased a new position in uniQure in the 3rd quarter worth approximately $53,000. Quarry LP purchased a new position in uniQure in the 3rd quarter worth approximately $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in uniQure in the 3rd quarter worth approximately $69,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on QURE shares. Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. The Goldman Sachs Group boosted their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Stifel Nicolaus boosted their target price on uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 16th. Mizuho boosted their target price on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. Finally, Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $40.00.

uniQure Trading Up 1.4 %

uniQure stock opened at $16.13 on Thursday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The business’s fifty day simple moving average is $14.29 and its two-hundred day simple moving average is $9.09. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a market capitalization of $786.18 million, a price-to-earnings ratio of -3.25 and a beta of 0.39.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. As a group, equities analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 4.74% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.